WARNING!
Bupropion xl generic vs brand
Is Bupropion The Generic For Wellbutrin
3-5 stars based on
120 reviews
Bupropion 150 mg for weight loss of less than 6 months and 300 mg for weight loss greater than 6 months have not been studied in a long-term trial. The efficacy and safety of bupropion or placebo should be carefully monitored in patients prescribed these pharmacologic agents, as bupropion and other weight reducing doses of antidepressants may increase cardiovascular Buy generic proscar uk mortality, especially in patients receiving higher doses. [see DRUG INTERACTIONS and ADVERSE REACTIONS]. Antabuse (nordihydroguaiaretic acid, USP) is a chemically related compound that, like bupropion, is a non-amphetamine derivative of nordihydroguaiaretic acid, a metabolite norepinephrine that has pharmacodynamic effect of slowing the central nervous system and is thought to be the cause of tachycardia observed in patients with obesity. The non-amphetamine half-life of metabolite in rodents is 3 to 4 hours, and the therapeutic range of antabuse nordihydroguaiaretic acid for the treatment of obesity is between 50 and 250 mg per day. The maximum estimated human clinical exposure to antabuse, however, is at low therapeutic doses, and studies to date have not identified any toxic effects at higher doses. The only drug-drug interaction with bupropion that was observed antabuse and is not expected to occur with antabuse in a large treatment course was reduction in efficacy of bupropion for depression on bupropion-containing medications. It is not known whether antabuse would increase bupropion clearance in patients on other antidepressant drugs. Antabuse or its metabolite can cause some degree of weight gain. At doses up to 300 mg daily, the maximum estimated human dose of antabuse was 1 to 3 grams per day. There is preliminary data suggesting that the drug may have some degree of stimulant effect at high doses (in excess of 500 mg daily), which may lead to a false and unhelpful impression of increased appetite. The effect drug on appetite was assessed in a randomized, double-blind, placebo-controlled clinical trial in obese women. Patients randomized to receive 500 1000 mg/day (at 5.0 to 6.5 kg/day body weight) of bupropion or placebo. The primary outcome was weight change. A comparison of the means for 2 groups of patients in the intention-to-treat approach for weight change demonstrated that in the bupropion group, weight gain was significantly greater than that with placebo at weeks 24, 36, and 52. Of the patients in bupropion group who were randomized to receive antabuse, 1/5 (12%) gained 50% of the weight in antabuse group; 1/4 (16%) gained 25% of the weight in antabuse group; 14/17 (63%) gained 15% of Pharmacy technician online courses uk the weight in antabuse group; 0/15 (0%) gained less than the baseline weight in antabuse group; and no subjects in either group gained at least 40% of their baseline weight. The most common adverse events involving antabuse were fatigue, headache, constipation, nausea, dizziness, insomnia, dry mouth, and tremor. Nausea is the most common side effect, and constipation, dysphoric mood, sweating, abnormal blood pressure, pulse, and heart rate were more com